兴齐眼药（300573）披露公司产品继续纳入医保目录，12月08日股价上涨0.16%

Core Viewpoint - The company Xingqi Eye Pharmaceutical (300573) has maintained a strong position in the national medical insurance drug list, which is expected to positively impact its long-term business performance [1]. Group 1: Stock Performance - As of December 8, 2025, Xingqi Eye Pharmaceutical's stock closed at 73.09 yuan, up 0.16% from the previous trading day [1]. - The stock opened at 73.19 yuan, reached a high of 74.18 yuan, and a low of 72.97 yuan, with a trading volume of 4.49 billion yuan and a turnover rate of 3.23% [1]. Group 2: National Medical Insurance Drug List - The National Healthcare Security Administration has included 39 products from Xingqi Eye Pharmaceutical in the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, with 8 in Category A and 31 in Category B, and no products being removed [1]. - Key products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Wash, and Sodium Hyaluronate Eye Drops continue to be included, while the restriction on the use of Gatifloxacin Eye Gel has been lifted [1]. - The new drug list will take effect on January 1, 2026, and is expected to have a long-term positive impact on the company's operating performance, although there is no significant short-term impact [1].